Healthcare > Pharmaceuticals & Biotechnology
•2438 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2438)
| Company | Market Cap | Price |
|---|---|---|
|
OPK
OPKO Health, Inc.
ModeX Therapeutics' multi-specific antibodies represent a bispecific antibody product category.
|
$1.06B |
$1.35
|
|
KURA
Kura Oncology, Inc.
Kura's core business is oncology-focused biotechnology developing ziftomenib and related menin inhibitors for AML, placing it in Biotech - Oncology.
|
$1.04B |
$11.98
+3.28%
|
|
BCAX
Bicara Therapeutics Inc. Common Stock
Directly focused on oncology therapeutics; Bicara's lead candidate is an antibody-based cancer therapy.
|
$1.04B |
$18.97
+2.76%
|
|
EYPT
EyePoint Pharmaceuticals, Inc.
Lead asset is an ophthalmic drug (DURAVYU) targeting wet AMD and DME.
|
$1.02B |
$14.78
+0.24%
|
|
TBPH
Theravance Biopharma, Inc.
Ampreloxetine is an oral small-molecule therapeutic in Phase 3 (CYPRESS) for symptomatic nOH in MSA, representing a core TBPH pipeline asset.
|
$1.01B |
$19.97
+5.44%
|
|
BHVN
Biohaven Ltd.
BHVN's Kv7 ion channel modulation platform (BHV-7000) and TRPM3 antagonist (BHV-2100) position the company in Ion Channel Modulators, a key neuroscience/pain modality.
|
$1.00B |
$9.51
+1.06%
|
|
VERV
Verve Therapeutics, Inc.
Verve Therapeutics' core offering is in vivo gene therapy using base editing delivered to liver cells, aligning with Biotech - Gene Therapy.
|
$988.30M |
$11.13
|
|
GLUE
Monte Rosa Therapeutics, Inc.
GLUE develops oral small-molecule molecular glue degraders (MGDs) as its core therapeutic modality.
|
$987.53M |
$15.97
-0.28%
|
|
NBTX
Nanobiotix S.A.
NBTXR3 is Nanobiotix's lead oncology therapy (hafnium oxide nanoparticle) used to enhance radiation therapy, fitting Biotech - Oncology.
|
$966.56M |
$20.20
-4.85%
|
|
DAWN
Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals markets and develops Oral Small Molecule Therapeutics (OJEMDA/tovorafenib) as a lead product.
|
$963.88M |
$9.42
-0.11%
|
|
SANA
Sana Biotechnology, Inc.
Sana's lead platform is HIP-modified cell therapy (ex vivo) for allogeneic cell transplantation.
|
$955.98M |
$4.03
+14.81%
|
|
PSNL
Personalis, Inc.
Biomarker-driven companion diagnostics align with PSNL's tumor-informed MRD testing framework.
|
$950.62M |
$10.71
-4.46%
|
|
SPRY
ARS Pharmaceuticals, Inc.
Neffy uses a proprietary Drug Delivery Platform enabling intranasal delivery of epinephrine.
|
$945.77M |
$9.57
+3.18%
|
|
AVBP
ArriVent BioPharma, Inc. Common Stock
Company focuses on oncology therapeutics, positioning it within Biotech - Oncology.
|
$935.11M |
$23.07
+1.29%
|
|
MRVI
Maravai LifeSciences Holdings, Inc.
Maravai produces highly modified nucleic acids (mRNA, oligonucleotides) and related inputs, including acquisitions expanding DNA/RNA production capabilities.
|
$929.52M |
$3.65
-2.93%
|
|
SVRA
Savara Inc.
Molgramostim is a recombinant GM-CSF protein delivered as an inhalation therapy; directly a recombinant protein/enzymes product.
|
$926.41M |
$5.37
+4.27%
|
|
FLGT
Fulgent Genetics, Inc.
Contract Research Organization services for bioPharma.
|
$922.86M |
$30.16
-2.25%
|
|
MNMD
Mind Medicine (MindMed) Inc.
MindMed's pipeline centers on neuropsychiatric drug development, placing it in the Neuropsychiatric Drug Development investable theme.
|
$920.66M |
$12.10
+1.85%
|
|
NTLA
Intellia Therapeutics, Inc.
Direct focus on CRISPR-based in vivo gene therapies (NTLA-2002 and nex-z) and a delivery platform, i.e., core gene-therapy biotech business.
|
$914.60M |
$8.53
-0.23%
|
|
RIGL
Rigel Pharmaceuticals, Inc.
Rigel's core products are oncology/hematology therapies (TAVALISSE, REZLIDHIA, GAVRETO), fitting Biotech - Oncology.
|
$914.09M |
$51.05
+3.01%
|
|
ARVN
Arvinas, Inc.
Lead program ARV-471 (vepdegestrant) is an oncology-focused asset, reflecting Arvinas' core business in cancer therapeutics and PROTAC technology.
|
$911.85M |
$12.41
+2.39%
|
|
ERAS
Erasca, Inc.
Erasa is a clinical-stage biotechnology company developing targeted cancer therapies, i.e., Biotech - Oncology.
|
$887.89M |
$3.13
+1.95%
|
|
VIR
Vir Biotechnology, Inc.
PRO-XTEN masking platform represents a drug delivery platform intended to improve safety and therapeutic index.
|
$887.68M |
$6.41
-0.47%
|
|
MLTX
MoonLake Immunotherapeutics
MoonLake focuses on immunology therapeutics with Sonelokimab (SLK) for inflammatory skin and joint diseases.
|
$886.38M |
$13.81
+1.47%
|
|
IOVA
Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics develops oncology therapeutics, with Amtagvi lifileucel representing an autologous TIL cell therapy for solid tumors.
|
$882.92M |
$2.44
-1.81%
|
|
LENZ
LENZ Therapeutics, Inc.
VIZZ is an aceclidine-based eye drop marketed as an ophthalmic drug for presbyopia.
|
$876.20M |
$30.67
+2.64%
|
|
RZLT
Rezolute, Inc.
Ersodetug is a human monoclonal antibody designed to treat HI by modulating insulin signaling, representing a monoclonal antibody therapeutic product.
|
$868.16M |
$9.54
+0.16%
|
|
ABUS
Arbutus Biopharma Corporation
Imdusiran is an RNA interference therapeutic (RNAi) targeting HBV, representing the core product category.
|
$845.39M |
$4.43
+2.55%
|
|
ATAI
Atai Beckley N.V
Acquisition of IntelGenx adds drug delivery platforms (oral thin-film) powering VLS-01 and related assets.
|
$803.77M |
$3.75
-0.27%
|
|
ESPR
Esperion Therapeutics, Inc.
Pipeline program for Primary Sclerosing Cholangitis, a rare liver disease.
|
$796.41M |
$3.96
+7.18%
|
Showing page 9 of 25 (2438 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
